张某与河南某药业公司分别向吉林某医药公司出具《承诺函》，就付款义务、违约责任、损失赔偿责 任、承担连带责任等作出承诺。 2024年，吉林某医药公司发现河南某药业公司和张某有挂网销售药品的行为，遂在多家电商平台回购了 发给河南某药业公司和张某的救心丸共计6531盒，并支付42.31万元。张某承认共窜货3000盒。 （来源：工人日报） 本报讯 （记者柳姗姗 彭冰 通讯员李雪）某公司签订了药品区域销售协议后，却将药品违约挂网销售、 擅自窜货。对于由此引发的高额违约金，法院将如何认定？近日，吉林省长春市绿园区人民法院审理了 这起合同纠纷案。 2023年1月，吉林某医药公司授权河南某药业公司、张某共同承包经营某救心丸在河南省区域的销售， 并签订协议约定代理商在承包期间不得超越代理范围，保证零售终端等下游客户不得有窜货、挂网销售 等不当行为，否则需支付惩罚性违约金。 河南某药业公司辩称，其与吉林某医药公司、张某之间实为挂靠关系，实际的药品销售方是吉林某医药 公司和张某。张某则表示，自己并没有将药品挂网销售、窜货，实际窜货人是其聘用的两位销售人员。 该案主审法官、长春市绿园区人民法院合心法庭庭长张季表示，依据相关法律法规， ...

Core Viewpoint - The inquiry transfer market in China's A-share market is experiencing rapid growth, with significant participation from both public and private funds, indicating a potential for becoming a foundational mechanism for share circulation in the capital market [1][3][5]. Group 1: Market Growth and Participation - Since 2026, 12 A-share listed companies have implemented inquiry transfer of shares, with various public and private fund institutions participating as buyers [1][3]. - The inquiry transfer market is expected to expand further, serving as a crucial bridge between the primary and secondary markets, enhancing market stability and supporting technological innovation [1][3]. - In 2025, the number of companies conducting inquiry transfers increased to 180 from just 12 in 2021, highlighting the market's rapid expansion [4]. Group 2: Performance and Returns - Many institutions participating in inquiry transfers have reported floating profits exceeding 30%, with 11 out of 12 companies involved seeing their stock prices rise above the initial transfer price [3][4]. - For example, Jiangbolong's transfer price was 212.09 yuan per share, with a closing price of 284.14 yuan, resulting in a floating profit rate of approximately 34% [3]. - The average return from inquiry transfers is projected to be 49.52% by the end of 2025, outperforming competitive public offerings [4]. Group 3: Strategic Insights - Inquiry transfers are becoming a significant strategy for public funds to achieve excess returns, with distinct risk-return characteristics compared to traditional private placements [5]. - The lower cost and higher efficiency of inquiry transfers allow investors to build positions more quickly, with returns primarily driven by price discounts and market valuation changes upon release [5]. - Future focus areas for investment strategies include sectors like semiconductors, AI hardware, and domestic software, where leading companies show enhanced visibility and growth certainty [6].

Core Viewpoint - The company, Bory Pharmaceutical (Suzhou) Co., Ltd., has announced that its subsidiary, Bory Pharmaceutical, is expected to be selected for the national drug procurement program, which could significantly impact its sales and market presence [1][2]. Group 1: Product Selection Details - The company participated in the national drug procurement program for products whose agreements have expired, with the selection results published on February 10, 2026 [1]. - Four products from the company are expected to be selected, which accounted for a total sales revenue of 88.8475 million yuan in the first three quarters of 2025, representing 10.16% of the company's total revenue during that period [2]. Group 2: Impact of Selection - The procurement cycle for the selected products will last until December 31, 2028, with medical institutions prioritizing the use of these selected drugs, which is expected to enhance sales volume and market share [2]. - If contracts are signed and implemented, it will further boost the company's brand image and sales performance [2].

关于开立募集资金现金管理专用结算账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 广州必贝特医药股份有限公司（以下简称"公司"）于2025年11月11日分别召开了第二届董事会审计委员 会2025年第五次会议、第二届董事会第七次（临时）会议、第二届监事会第七次（临时）会议，审议通 过了《关于使用部分暂时闲置募集资金进行现金管理的议案》，同意公司及公司子公司使用额度不超过 人民币9.00亿元（含本数）的暂时闲置募集资金进行现金管理，用于购买安全性高、流动性好、满足保 本需求的理财产品或存款类产品。具体内容详见公司于2025年11月13日在上海证券交易所网站 （www.sse.com.cn）上披露的《关于使用部分暂时闲置募集资金进行现金管理的公告》（公告编号： 2025-004）。 一、开立募集资金现金管理专用结算账户情况 因募集资金现金管理的需要，公司近日在中信证券华南股份有限公司、国泰海通证券股份有限公司开立 了募集资金现金管理专用结算账户，具体信息如下： ■ 广州必贝特医药股份有限公司 4、公司财务部相关人员将及 ...

Summary of Praxis Precision Medicines Conference Call Company Overview - **Company**: Praxis Precision Medicines (NasdaqGS:PRAX) - **Event**: Guggenheim Emerging Outlook, Biotech Summit 2026 - **Date**: February 11, 2026 - **Key Executives Present**: Marcio Souza (CEO), Tim Kelly (CFO) Core Industry Insights - **Focus Area**: Central Nervous System (CNS) disorders, specifically essential tremor and epilepsy treatments - **Market Potential**: Approximately 2-2.5% of the U.S. population is affected by essential tremor, indicating a significant patient base requiring treatment [9][10] - **Current Treatment Landscape**: There are no effective and safe treatments available for essential tremor, highlighting a substantial unmet medical need [10] Key Points Discussed - **Ulixacaltamide Hydrochloride**: - A potential drug for essential tremor, expected to be a significant advancement in treatment options [9][10] - Positive results from the Essential3 program were highlighted, indicating meaningful benefits for patients [11] - **Patient Population**: - Between 1 and 2 million patients in the U.S. are actively seeking treatment for essential tremor [16] - 80,000 prescriptions are written monthly by neurologists for essential tremor, indicating strong demand [14] - 70% of patients have family members also affected by essential tremor, suggesting a broader market potential [19] - **Commercial Strategy**: - The company plans to deploy a robust sales force to effectively reach physicians across the U.S. [21] - Emphasis on mobilizing patients to participate in clinical studies, achieving recruitment rates 5-7 times faster than larger competitors [24] - The launch strategy will include extensive patient messaging and ensuring coverage from payers [27] - **Pricing Strategy**: - Initial pricing discussions suggest a potential range of $40,000 to $60,000 per year for ulixacaltamide, with considerations for patient copay management [43][44] - The company aims to avoid leaving money on the table to ensure continued innovation [41] Regulatory and Development Updates - **NDA Filing**: - The company is on track to file for ulixacaltamide in mid-February 2026, with confidence in meeting regulatory requirements [47][52] - Two NDAs are being filed simultaneously, indicating a significant operational effort [60] - **Emerald Study**: - The EMERALD study for expanding indications in developmental and epileptic encephalopathies (DEE) is progressing well, with expectations for positive outcomes [64][66] - The study is anticipated to finalize in the second half of the year, potentially qualifying for expedited review under the STAR program [67] Financial Position - **Funding**: - The company has approximately $1.5 billion in cash, providing a strong runway to support drug launches and operations through 2028 [90] - **Priority Vouchers**: - The company is eligible for two priority review vouchers, which could enhance its market positioning for rare disease treatments [90] Additional Considerations - **Market Dynamics**: - The company acknowledges the competitive landscape for epilepsy treatments but believes there is ample opportunity for multiple successful products [78] - **Combination Therapies**: - Future treatments may involve combination therapies, particularly for severe cases, indicating a strategic approach to patient care [86] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Praxis Precision Medicines' focus on addressing significant unmet needs in CNS disorders and its proactive approach to market entry and patient engagement.

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. has completed the registration capital change and has received a new business license following the cancellation of part of its restricted stock incentive plan [1][4]. Group 1: Company Actions - The company held a board meeting on September 17, 2025, and a temporary shareholders' meeting on November 24, 2025, where it approved the proposal to change its registered capital and amend the Articles of Association [1]. - The company repurchased and canceled 3,000 shares from its 2022 restricted stock incentive plan, leading to a reduction in registered capital by 3,000 yuan [1]. Group 2: Registration Details - The new registered capital of the company is 316,354,550 yuan [1]. - The company is classified as a joint-stock company and is located in Harbin, with its legal representative being Qin Jianfei [1]. Group 3: Business Scope - The company is involved in various sectors including drug production, wholesale and retail, cosmetics production, food production, and medical device manufacturing [1][2]. - It also engages in internet sales of food and health products, as well as providing inspection and testing services [2].

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has participated in the national organized procurement for expiring drug agreements and has several products expected to be selected for continued procurement, which is anticipated to positively impact the company's market share and future operating performance [1][2]. Group 1: Announcement of Selected Products - The company participated in the national organized procurement for expiring drug agreements on February 9, 2026, and has several key products expected to be selected for this procurement [1]. - The selected products include the top five in terms of revenue scale, with additional products such as Venlafaxine Hydrochloride Sustained-Release Capsules also participating [1]. - The procurement cycle for the selected products will run from the date of selection until December 31, 2028 [1]. Group 2: Impact of Selection on the Company - The expected selection of products is projected to stabilize the company's existing market share despite a decrease in sales prices [2]. - The company aims to leverage its brand influence and reliable supply capabilities to further increase its market share, which is expected to have a positive impact on future operating performance [2]. - The implementation of the procurement results is anticipated to begin by the end of March 2026, with provincial medical institutions signing procurement contracts based on the selection results [2].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603669 证券简称：灵康药业（维权） 公告编号：2026-008 灵康药业集团股份有限公司 关于控股股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 公司控股股东灵康控股集团有限公司（以下简称"灵康控股"）直接及间接持有公司股份33,965.28万股 无限售流通股股票，占公司总股本的47.09%，灵康控股本次解除质押的股份4,965.96万股，占其持有公 司股份总数的14.62%，占公司总股本的6.89%。 2026年2月11日，灵康药业集团股份有限公司（以下简称"灵康药业"或"公司"）接到公司控股股东灵康 控股关于部分股份解除质押的通知，现将相关情况公告如下： ■ 经与灵康控股确认，解除质押的股份暂无后续质押计划。后续如有变动，公司将根据相关法律法规要求 及时履行信息披露义务。 特此公告。 灵康药业集团股份有限公司董事会 2026年2月12日 ...

Group 1: Board Election Announcement - The company announced the election of Mr. Zhao Yong as the employee representative director of the eighth board of directors, following the approval of the employee representative conference held on February 11, 2026 [1][3] - Mr. Zhao Yong meets the qualifications and conditions for the position as stipulated by relevant laws and the company's articles of association [1] - The number of directors who are also senior management and those who are employee representatives does not exceed half of the total number of directors, complying with legal requirements [1] Group 2: Stock Option Incentive Plan - The company reported that 680,000 stock options from the third exercise period of the 2019 A-share stock option incentive plan were available for exercise from February 8, 2025, to February 7, 2026 [5] - No stock options were exercised during the third exercise period, and the unexercised options will be canceled by the company [6][17] - The total share capital of the company as of the end of the third exercise period was 3,708,361,809 shares, and the lack of exercised options did not significantly impact the company's financial status [22] Group 3: Approval of Raw Material Drug - The company announced that its subsidiary, Shanghai Pharmaceutical Kangli, received approval from the National Medical Products Administration for the production of Tamsulosin hydrochloride [23][24] - Tamsulosin hydrochloride is a third-generation selective long-acting α1 blocker used for treating benign prostatic hyperplasia (BPH) [25] - The company has invested approximately RMB 1.5 million in research and development for this drug, which is expected to enhance its market presence [26]

Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management, ensuring that it does not affect the normal investment plan and guarantees fund safety [2]. Group 1: Cash Management Plan - The company intends to use up to RMB 200,000,000 (including principal) of idle raised funds for cash management, focusing on high-security, good liquidity, and capital preservation bank deposit products [2]. - The cash management products may include but are not limited to agreement deposits, time deposits, and large-denomination certificates of deposit, with a maximum term of 12 months [2]. - This cash management plan does not require submission for shareholder meeting approval [2]. Group 2: Current Status of Cash Management - As of the announcement date, the company has a remaining balance of RMB 54,000,000 from the temporarily idle raised funds used for cash management [2]. - The highest daily balance and usage period of the idle raised funds for cash management have not exceeded the authorization range set by the company's board of directors [2].